Atara Biotherapeutics, Inc. $ATRA Shares Acquired by Globeflex Capital L P

Globeflex Capital L P grew its position in Atara Biotherapeutics, Inc. (NASDAQ:ATRA) by 399.6% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 77,224 shares of the biotechnology company’s stock after purchasing an additional 61,766 shares during the period. Globeflex Capital L P’s holdings in Atara Biotherapeutics were worth $1,397,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also modified their holdings of ATRA. Marshall Wace LLP acquired a new position in shares of Atara Biotherapeutics in the 2nd quarter valued at about $327,000. Mackenzie Financial Corp lifted its stake in shares of Atara Biotherapeutics by 183.5% in the 3rd quarter. Mackenzie Financial Corp now owns 63,816 shares of the biotechnology company’s stock valued at $914,000 after purchasing an additional 41,302 shares in the last quarter. Vanguard Group Inc. lifted its stake in shares of Atara Biotherapeutics by 6.6% in the 3rd quarter. Vanguard Group Inc. now owns 203,438 shares of the biotechnology company’s stock valued at $2,915,000 after purchasing an additional 12,677 shares in the last quarter. GSA Capital Partners LLP lifted its stake in shares of Atara Biotherapeutics by 33.8% in the 3rd quarter. GSA Capital Partners LLP now owns 26,213 shares of the biotechnology company’s stock valued at $376,000 after purchasing an additional 6,622 shares in the last quarter. Finally, Raymond James Financial Inc. acquired a new position in shares of Atara Biotherapeutics in the 2nd quarter valued at about $31,000. 70.90% of the stock is owned by institutional investors and hedge funds.

Insider Activity at Atara Biotherapeutics

In related news, CEO Anhco Nguyen sold 5,241 shares of the business’s stock in a transaction that occurred on Monday, May 18th. The stock was sold at an average price of $9.13, for a total transaction of $47,850.33. Following the transaction, the chief executive officer directly owned 137,837 shares of the company’s stock, valued at approximately $1,258,451.81. The trade was a 3.66% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, major shareholder Innovation Ltd Panacea sold 313,446 shares of the business’s stock in a transaction that occurred on Thursday, May 7th. The stock was sold at an average price of $10.10, for a total value of $3,165,804.60. Following the transaction, the insider directly owned 1,011,000 shares in the company, valued at $10,211,100. This trade represents a 23.67% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 321,101 shares of company stock worth $3,235,695 over the last three months. 41.20% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

ATRA has been the topic of several research analyst reports. Freedom Capital raised Atara Biotherapeutics from a “strong sell” rating to a “hold” rating in a research note on Monday, May 18th. Wall Street Zen raised Atara Biotherapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, May 16th. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Atara Biotherapeutics in a research note on Friday, March 27th. Finally, Canaccord Genuity Group set a $13.00 price objective on Atara Biotherapeutics and gave the company a “buy” rating in a research note on Friday, May 8th. One investment analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Hold” and a consensus target price of $9.50.

Atara Biotherapeutics Stock Performance

Atara Biotherapeutics stock opened at $10.31 on Friday. The stock’s 50 day moving average price is $6.96 and its 200 day moving average price is $8.77. The firm has a market capitalization of $92.89 million, a PE ratio of -15.39 and a beta of 0.11. Atara Biotherapeutics, Inc. has a one year low of $3.92 and a one year high of $19.15.

Atara Biotherapeutics (NASDAQ:ATRA) last released its quarterly earnings results on Tuesday, May 12th. The biotechnology company reported ($0.29) EPS for the quarter, topping the consensus estimate of ($0.33) by $0.04. The firm had revenue of $0.52 million for the quarter, compared to analyst estimates of $2.90 million. Atara Biotherapeutics had a negative return on equity of 79.12% and a negative net margin of 40.91%. On average, analysts forecast that Atara Biotherapeutics, Inc. will post 0.2 earnings per share for the current fiscal year.

Atara Biotherapeutics Profile

Atara Biotherapeutics, Inc is a biotechnology company focused on the discovery, development and commercialization of novel T-cell immunotherapies to transform the treatment of cancer and autoimmune disease. Headquartered in South San Francisco, California, Atara leverages its proprietary off-the-shelf allogeneic Epstein-Barr virus (EBV)-directed T-cell platform to generate engineered cell therapies designed to target EBV-driven malignancies and immune-mediated disorders.

The company’s lead product candidate, tabelecleucel, is an off-the-shelf, EBV-specific T-cell therapy in clinical development for the treatment of EBV-positive post-transplant lymphoproliferative disease (PTLD) and other EBV-associated cancers.